Opendata, web and dolomites

TheraPD TERMINATED

TheraPD: Smart and safer automated peritoneal dialysis by means of sterile connectivity, bio-sensors control systems and more biocompatible solutions for preventing rapid degradation of peritoneal mem

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TheraPD project word cloud

Explore the words cloud of the TheraPD project. It provides you a very rough idea of what is the project "TheraPD" about.

budgets    cells    65    250    penetrating    therapy    solving    patient    glucose    reduce    rapid    dialysate    ec    benefits    disease    home    healthcare    earning    causing    expanding    peritonitis    people    membrane    comfort    societal    machine    spending    consist    capacity    roi    ph    3h    esrd    equipped    million    unmet    launch    profit    therapd    transplant    demonstrated    dropout    concentration    overfilling    clinical    customize    biocompatible    dialysis    special    safe    stage    poorly    hospital    risk    eligible    irreversible    individual    7m    degradation    innovative    biosensors    generating    solution    avoids    monitor    haemodialysis    europeans    treatment    worldwide    transplants    renders    body    least    doubled    connector    ultrafiltration    solutions    patients    cavity    sterile    peritoneal    nhs    undergo    15    frequency    35    innovation    11    mesothelium    kidney    significantly    cycler    solid    outcome    biosensing    efficient    renal    almost    prescription       drawbacks    connected    world    automated       date    either    pd    times    prevents    week    safety    zero    market    previously    entails   

Project "TheraPD" data sheet

The following table provides information about the project.

Coordinator
GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA 

Organization address
address: VIA PADRE UGOLINO FRASCA, SNC
city: CHIETI
postcode: 66100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://youtu.be/YGVClIl33qs
 Total cost 2˙838˙126 €
 EC max contribution 2˙838˙126 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA IT (CHIETI) coordinator 2˙838˙126.00

Map

 Project objective

2.7 million People worldwide (250,000 Europeans) have kidney transplants or undergo a dialysis treatment because of irreversible end-stage renal disease (ESRD). This number has more than doubled over the past 15 years and involves 3-5% of NHS budgets. Current therapy consist in either a kidney transplant, haemodialysis connected to a machine at the hospital for at least 3h, 3 times a week, or the better-outcome cost-effective home-based peritoneal dialysis (PD). Although widely demonstrated to have greater results and to be cost-effective, PD is only used in 11% of the cases because of its drawbacks: peritonitis (35% dropout), poorly biocompatible solutions available, and overfilling of the peritoneal cavity causing rapid degradation on the mesothelium membrane. Our innovative TheraPD solution provide the most safe and efficient automated peritoneal dialysis therapy to date. It entails a comprehensive system composed by a sterile connector (renders peritonitis risk almost zero), a biosensing control system (avoids overfilling), and a new biocompatible dialysate which prevents degradation of peritoneal membrane cells. Another innovation is that our cycler will be equipped with special biosensors to measure the concentration of glucose and pH, this allows to customize the dialysis prescription according to the ultrafiltration capacity of the patient, increases safety level of the treatment and it allows to monitor the uptake of glucose by the patient. By solving these unmet clinical needs, we will increase PD usage by expanding it to people who were not previously eligible, reduce treatment frequency or duration, customize the dialysis treatment according to the response of the patient’s body, increase patients’ comfort and significantly reduce healthcare spending. With EC’s support we will achieve all these societal and individual benefits while earning €4.7M profit, penetrating 1.15% of the world market, and generating a solid ROI of 1.65 after 5 years from launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More